+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cerus Corp (CERS) - Product Pipeline Analysis, 2020 Update

1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Grifols SA
  • Kedrion Biopharma Inc
  • Octapharma AG
  • Terumo BCT Inc
  • MORE
Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes Intercept Blood System, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for use with three blood components,: platelets, plasma and red blood cells. Cerus’ Intercept blood system is marketed and sold by its direct sales force and distributors in several countries worldwide including the US, Belgium, Kuwait, France, Spain, Portugal, Switzerland, Commonwealth of Independent States (CIS) countries and other countries. Cerus is headquartered in Concord, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Cerus Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Grifols SA
  • Kedrion Biopharma Inc
  • Octapharma AG
  • Terumo BCT Inc
  • MORE
Cerus Corp Company Overview
  • Cerus Corp Company Snapshot
  • Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
  • Cerus Corp - Pipeline Analysis Overview
  • Business Description
  • Cerus Corp - Key Facts
  • Cerus Corp - Major Products and Services
  • Cerus Corp Pipeline Products by Development Stage
  • Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Pipeline Products Overview
  • INTERCEPT Blood System - Platelets
  • INTERCEPT Blood System - Platelets Product Overview
  • INTERCEPT Blood System - Platelets Clinical Trial
  • INTERCEPT Blood System - Red Blood Cells
  • INTERCEPT Blood System - Red Blood Cells Product Overview
  • INTERCEPT Blood System - Red Blood Cells Clinical Trial
  • INTERCEPT Blood System - Whole Blood
  • INTERCEPT Blood System - Whole Blood Product Overview
  • INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma
  • INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma Product Overview
  • Next Generation INTERCEPT Blood System
  • Next Generation INTERCEPT Blood System Product Overview
  • NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex
  • NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex Product Overview
Cerus Corp - Key Competitors

Cerus Corp - Key Employees
  • Cerus Corp - Key Employee Biographies
Cerus Corp - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • Cerus Corp, Recent Developments
  • Apr 02, 2020: Cerus Corporation announces the inclusion of pathogen reduction technology in the ISBT working party recommendations for the preparation of COVID-19 convalescent plasma
  • Feb 18, 2020: U.S. Department of Defense awards funding for study to evaluate the use of INTERCEPT Plasma in traumatic burn resuscitation
  • Jan 23, 2020: Coronavirus inactivation reported in recent INTERCEPT Blood System publication in transfusion medicine
  • Jan 21, 2020: French Hemovigilance report highlights safety and effectiveness of INTERCEPT Platelets during first full year of 100% production and routine use
  • Oct 30, 2019: Cerus announces third quarter 2019 results
  • Oct 18, 2019: Cerus announces schedule of presentations at the 2019 AABB Annual Meeting
  • Sep 30, 2019: Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion
  • Aug 01, 2019: Cerus announces record second quarter 2019 results
  • Jun 24, 2019: Cerus announces presentations highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT
  • Jun 03, 2019: Cerus announces new corporate brand and global headquarters
Appendix
  • Methodology
  • About the Publisher
  • Contact Us
  • Disclaimer
List of Tables
  • Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
  • Cerus Corp Pipeline Products by Equipment Type
  • Cerus Corp Pipeline Products by Indication
  • Cerus Corp Ongoing Clinical Trials by Trial Status
  • Cerus Corp, Key Facts
  • Cerus Corp, Major Products and Services
  • Cerus Corp Number of Pipeline Products by Development Stage
  • Cerus Corp Pipeline Products Summary by Development Stage
  • Cerus Corp Ongoing Clinical Trials by Trial Status
  • Cerus Corp Ongoing Clinical Trials Summary
  • INTERCEPT Blood System - Platelets - Product Status
  • INTERCEPT Blood System - Platelets - Product Description
  • INTERCEPT Blood System - Platelets - A Randomized, Multi-center, Multi-Stage, Controlled, In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
  • INTERCEPT Blood System - Red Blood Cells - Product Status
  • INTERCEPT Blood System - Red Blood Cells - Product Description
  • INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures
  • INTERCEPT Blood System - Red Blood Cells - Measurement of the Recovery and Lifespan of Red Blood Cells from Pathogen-reduced, Stored Blood Units Using Cellular Biotinylation
  • INTERCEPT Blood System - Red Blood Cells - Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections and Treatment Use Open-label Extension Study
  • INTERCEPT Blood System - Whole Blood - Product Status
  • INTERCEPT Blood System - Whole Blood - Product Description
  • INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma - Product Status
  • INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma - Product Description
  • Next Generation INTERCEPT Blood System - Product Status
  • Next Generation INTERCEPT Blood System - Product Description
  • NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex - Product Status
  • NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex - Product Description
  • Cerus Corp, Key Employees
  • Cerus Corp, Key Employee Biographies
  • Cerus Corp, Subsidiaries
  • Glossary
List of Figures
  • Cerus Corp Pipeline Products by Equipment Type
  • Cerus Corp Pipeline Products by Development Stage
  • Cerus Corp Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 3
  • Terumo BCT Inc
  • Octapharma AG
  • MacoPharma International Gmbh
  • Kedrion Biopharma Inc
  • Grifols SA
Note: Product cover images may vary from those shown
Adroll
adroll